Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 938 000 KRW -1.16%
Market Cap: 66.8T KRW
Have any thoughts about
Samsung Biologics Co Ltd?
Write Note

Samsung Biologics Co Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Samsung Biologics Co Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Samsung Biologics Co Ltd
KRX:207940
Change in Working Capital
â‚©76.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Change in Working Capital
â‚©2.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Change in Working Capital
-â‚©10.6B
CAGR 3-Years
29%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Change in Working Capital
â‚©2B
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Change in Working Capital
â‚©53.4B
CAGR 3-Years
55%
CAGR 5-Years
97%
CAGR 10-Years
N/A
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Change in Working Capital
â‚©3.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Samsung Biologics Co Ltd
Glance View

Market Cap
66.8T KRW
Industry
Life Sciences Tools & Services

In the bustling world of biopharmaceuticals, Samsung Biologics Co Ltd has carved a niche as a formidable player, merging cutting-edge technology with industrial scale to drive its operations. Situated in Incheon, South Korea, the company emerged as a key subsidiary of Samsung Group, bringing with it the organizational prowess and strategic vision that hallmark the conglomerate. Established with the goal of reshaping the global landscape of biopharmaceutical manufacturing, Samsung Biologics offers a suite of contract development and manufacturing organization (CDMO) services. From early-stage development to large-scale production, the company supports clients through every step of a biologic's lifecycle, ensuring seamless transition from laboratory to patient. The blend of state-of-the-art facilities and advanced process technologies enables them to meet the growing demands for complex biopharmaceuticals efficiently. Samsung Biologics' revenue machine spins around its comprehensive service spectrum, which includes drug substance and product manufacturing and laboratory testing services. The contract-based model allows global pharma companies to outsource crucial parts of their development and manufacturing processes to Samsung Biologics, thus optimizing costs and timelines. By building strategic partnerships and continuously investing in expanding its manufacturing capacity, Samsung Biologics not only captures market share but also aligns itself with the burgeoning demand for biosimilars and other next-generation therapeutics. Furthermore, operating within a highly regulated and competitive industry, the company's focus on maintaining stringent quality standards and regulatory compliance cements its reputation as a trusted partner in the pharmaceutical sector.

Intrinsic Value
490 513.26 KRW
Overvaluation 48%
Intrinsic Value
Price

See Also

What is Samsung Biologics Co Ltd's Change in Working Capital?
Change in Working Capital
76.4B KRW

Based on the financial report for Sep 30, 2024, Samsung Biologics Co Ltd's Change in Working Capital amounts to 76.4B KRW.

Back to Top